National ALS Clinic and Research Group, Beaumont Hospital Dublin/Academic Unit of Neurology

Trinity College Dublin

The National ALS Clinic and Research Group based at Beaumont Hospital Dublin provides a multidisciplinary service to the entire Irish ALS population.

 

Trinity College Dublin

The National ALS Clinical and Research Group undertakes research in epidemiology, cognition, genetics, bioinformatics, drug development and novel biomarker development, and commercial and investigator led clinical trials of novel compounds in ALS. Much of our clinical research is supported by the charity Research Motor Neurone.

Contact
Location
School of Medicine, Trinity Biomedical Sciences Institute, Pearse Street, Dublin 2, Dublin, Ireland

Our Specialists

Orla Hardiman

Professor of Neurology

Professor Hardiman trained in Neurology in Boston prior to her appointment as […]

Orla Hardiman
Current trials
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Active
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more